lapatinib has been researched along with thiourea in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (thiourea) | Trials (thiourea) | Recent Studies (post-2010) (thiourea) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 6,959 | 46 | 1,737 |
| Protein | Taxonomy | lapatinib (IC50) | thiourea (IC50) |
|---|---|---|---|
| Urease | Canavalia ensiformis (jack bean) | 0.56 | |
| Serine-protein kinase ATM | Homo sapiens (human) | 0.2 | |
| Serine/threonine-protein kinase ATR | Homo sapiens (human) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, G; Yang, B; Yang, N; Yang, YS; Zhu, HL | 1 |
1 other study(ies) available for lapatinib and thiourea
| Article | Year |
|---|---|
Design, biological evaluation and 3D QSAR studies of novel dioxin-containing pyrazoline derivatives with thiourea skeleton as selective HER-2 inhibitors.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dioxins; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lapatinib; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship; Quinazolines; Receptor, ErbB-2; Thiourea | 2016 |